Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia

The understanding of the B cell receptor (BCR) pathway and its contribution to chronic lymphocytic leukemia (CLL) pathogenesis have led to the development of targeted BCR inhibitors which have transformed the treatment paradigm of CLL. Ibrutinib is a first-in-class oral Bruton’s tyrosine kinase (BTK...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhodes, Joanna M, Mato, Anthony R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936706/
https://www.ncbi.nlm.nih.gov/pubmed/33688166
http://dx.doi.org/10.2147/DDDT.S250823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936706/
https://www.ncbi.nlm.nih.gov/pubmed/33688166
http://dx.doi.org/10.2147/DDDT.S250823

Ejemplares similares